Pharming Group NV/ NL0010391025 /
9/4/2024 8:25:55 PM | Chg. -0.0702 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.7547USD | -8.51% | 850 Turnover: 641.4950 |
-Bid Size: - | -Ask Size: - | 0.7547 | 0.7547 |
GlobeNewswire
8/1
Pharming Group reports second quarter and first half 2024 financial results and provides business up...
GlobeNewswire
7/18
Pharming Group to report second quarter and first half 2024 financial results on August 1
GlobeNewswire
5/21
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
GlobeNewswire
5/8
Pharming Group reports first quarter 2024 financial results and provides business update
GlobeNewswire
4/24
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 20...
GlobeNewswire
4/8
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
GlobeNewswire
2/29
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
GlobeNewswire
1/8
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
GlobeNewswire
12/13/2023
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies ...
GlobeNewswire
11/21/2023
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years fo...
GlobeNewswire
11/13/2023
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Acc...
GlobeNewswire
10/12/2023
Pharming Group to report third quarter 2023 financial results on October 26
GlobeNewswire
9/25/2023
Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
GlobeNewswire
1/10/2022
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene The...
GlobeNewswire
11/4/2021
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Upd...